SuperworthNeurocrine Biosciences shares outstanding NBIX
Diluted shares outstanding, averaged over each quarter, from 2010.
- Latest quarter, to Jun 30, 2026
- 104.2M
- On a year earlier
- +3.2%
- more shares
Neurocrine Biosciences had 104.2M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 3.2% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 104M | +1% |
| FY2024 | 102.8M | +1% |
| FY2023 | 102.2M | +1% |
| FY2022 | 100.7M | +6% |
| FY2021 | 94.9M | −2% |
| FY2020 | 97.2M | −0% |
| FY2019 | 97.2M | +2% |
| FY2018 | 95.7M | +3% |
| FY2017 | 92.7M | +7% |
| FY2016 | 86.9M | +1% |
| FY2015 | 86.2M | +13% |
| FY2014 | 76.1M | +13% |
| FY2013 | 67.3M | −1% |
| FY2012 | 67.7M | +20% |
| FY2011 | 56.5M | +3% |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 104.2M | +3% | |
| Q1 FY26 | 103.4M | +1% | |
| Q4 FY25 | 104M | +1% | |
| Q3 FY25 | 102.5M | −2% | |
| Q2 FY25 | 101M | −3% | |
| Q1 FY25 | 102.5M | −1% | |
| Q4 FY24 | 102.8M | +1% | |
| Q3 FY24 | 104.3M | +3% | |
| Q2 FY24 | 103.9M | +4% | |
| Q1 FY24 | 103.6M | +7% | |
| Q4 FY23 | 102.2M | +1% | |
| Q3 FY23 | 101.1M | +2% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Neurocrine Biosciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.